09.07.2015 Views

guidelines on variations to a registered pharmaceutical product

guidelines on variations to a registered pharmaceutical product

guidelines on variations to a registered pharmaceutical product

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Guidelines <strong>on</strong> Variati<strong>on</strong>s <strong>to</strong> a Registered Pharmaceutical ProductDescripti<strong>on</strong> of changeC<strong>on</strong>diti<strong>on</strong>s <strong>to</strong>be fulfilledDocumentati<strong>on</strong>requiredReportingtype30 Change in c<strong>on</strong>centrati<strong>on</strong> of a single-dose, <strong>to</strong>taluse parenteral <strong>product</strong>, where the amoun<strong>to</strong>f active substance per unit dose (i.e. thestrength) remains the sameVmajDescripti<strong>on</strong> of changeC<strong>on</strong>diti<strong>on</strong>s <strong>to</strong>be fulfilledDocumentati<strong>on</strong>requiredReportingtype31 Deleti<strong>on</strong> of the solvent/diluent c<strong>on</strong>tainer fromthe packDocumentati<strong>on</strong> requiredN<strong>on</strong>e 1-3 Vmaj1. Justificati<strong>on</strong> for the deleti<strong>on</strong>, including a statement regarding alternative means <strong>to</strong> obtain the solvent/diluent as required for the safe and effective use of the <strong>pharmaceutical</strong> <strong>product</strong>.2. Revised <strong>product</strong> informati<strong>on</strong>3. Samples of the <strong>product</strong>5.3.2.2 ManufactureDescripti<strong>on</strong> of changeC<strong>on</strong>diti<strong>on</strong>s <strong>to</strong>be fulfilledDocumentati<strong>on</strong>requiredReportingtype32 Additi<strong>on</strong> or replacement of a manufacturing site for part or all of the manufacturing process for afinished <strong>pharmaceutical</strong> <strong>product</strong> involving32a sec<strong>on</strong>dary packaging of all types of FPPs 2-3 1 IN32bprimary packaging site of32b.1 solid FPPs (e.g. tablets, capsules) ,semisolid (e.g. ointments, creams) andsoluti<strong>on</strong> liquid FPPs2-4 1,8 IN32b.2 other liquid FPPs (suspensi<strong>on</strong>s, emulsi<strong>on</strong>s) 2-5 1,5,8 IN32call other manufacturing operati<strong>on</strong>s exceptbatch c<strong>on</strong>trol/release testing1-3,5 1-9 VminDoc. No.: DAR/GDL/005 Revisi<strong>on</strong> Date: 8 th July 2013 Review Due Date: 16 th July 2016Revisi<strong>on</strong> No.: 1 Effective Date : 16 th July 2013 Page 41 of 70

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!